Furthermore we continue to believe that patients treated in the Zalutumumab
pivotal study were sicker than patients treated in similar disease setting with
Erbitux +/- Chemo. For instance 65% had distant metastasis in the
Zalutumumab study and all patient
Derudover kommer der data fra yderligere to studier:
However we do not expect a BLA-filing with the FDA until mid-2012 as
Genmab most likely will await 12-months survival data from the 100 patients
US phase II study conducted in recurrent/metastatic Head
Head and Neck cancer.
Data should be out in Q1 2012.
In 2012 we also expect interim data from the 600 patients frontline Head and
Neck cancer study carried out by the Danish organization DAHANCA.
According to the protocol there is an interim analysis plan
Enig, men det er måske årsagen til at Genmab har kunnet tale sig til rette med EMA
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.